Stock ALPN ALPINE IMMUNE SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Alpine Immune Sciences, Inc.

Equities

ALPN

US02083G1004

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 17/05/2024 BST 		5-day change 1st Jan Change
64.97 USD +0.02% Intraday chart for Alpine Immune Sciences, Inc. -.--% +240.87%
05-20 Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from NASDAQ Composite Index CI
05-20 Vertex Pharmaceuticals Incorporated completed the acquisition of Alpine Immune Sciences, Inc. from a group of shareholders. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 50.98 71.38 299.9 404.7 337.5 1,106
Enterprise Value (EV) 1 2.877 47.21 216.9 262 114.1 788
P/E ratio -1.4 x -1.68 x -9.39 x -6.99 x -4.25 x -29.6 x
Yield - - - - - -
Capitalization / Revenue 72.3 x 41 x 32.1 x 17.3 x 11.2 x 18.8 x
EV / Revenue 4.08 x 27.1 x 23.2 x 11.2 x 3.79 x 13.4 x
EV / EBITDA -0.08 x -1.1 x -7.7 x -5.32 x -1.98 x -18 x
EV / FCF -0.19 x -2.04 x 14 x -9.86 x -10.2 x -27.1 x
FCF Yield -535% -49% 7.12% -10.1% -9.76% -3.69%
Price to Book 1.14 x 2.42 x 4.83 x 3.46 x 1.88 x 3.51 x
Nbr of stocks (in thousands) 13,852 18,588 23,803 29,220 45,914 58,002
Reference price 2 3.680 3.840 12.60 13.85 7.350 19.06
Announcement Date 18/03/19 30/03/20 18/03/21 17/03/22 23/03/23 20/03/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 0.705 1.74 9.335 23.44 30.06 58.88
EBITDA 1 -36.24 -43.11 -28.17 -49.24 -57.55 -43.67
EBIT 1 -36.63 -43.57 -28.75 -49.86 -58.15 -44.25
Operating Margin -5,195.32% -2,504.25% -307.97% -212.68% -193.41% -75.16%
Earnings before Tax (EBT) 1 -36.85 -41.85 -27.95 -50.42 -55.43 -32.08
Net income 1 -36.49 -41.85 -27.94 -50.33 -57.76 -32.18
Net margin -5,175.46% -2,405.29% -299.3% -214.7% -192.13% -54.66%
EPS 2 -2.635 -2.280 -1.342 -1.980 -1.730 -0.6437
Free Cash Flow 1 -15.39 -23.11 15.45 -26.57 -11.13 -29.06
FCF margin -2,183.58% -1,328.33% 165.49% -113.33% -37.01% -49.36%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 18/03/19 30/03/20 18/03/21 17/03/22 23/03/23 20/03/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2026
Net Debt - - - - - -
Net Cash position - - - 223 327 -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - - - - - -
ROE (net income / shareholders' equity) - - - -38.5% -12.7% -
ROA (Net income/ Total Assets) - - - - - -
Assets - - - - - -
Book Value Per Share - - - 3.900 - -
Cash Flow per Share - - - - - -
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 30/03/20 18/03/21 17/03/22 23/03/23 18/03/24 -
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ALPINE IMMUNE SCIENCES, INC. Stock Alpine Immune Sciences, Inc.
+240.87% 4.46B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.73% 123B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+21.13% 115B
ARGENX SE Stock argenx SE
+18.05% 25.85B
BIONTECH SE Stock BioNTech SE
-17.94% 20.9B
GENMAB A/S Stock Genmab A/S
-16.24% 16.52B
BEIGENE, LTD. Stock BeiGene, Ltd.
-11.76% 16.77B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-44.45% 15.56B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+69.92% 15.49B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+1.41% 13.45B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ALPN Stock
  4. Financials Alpine Immune Sciences, Inc.